CRDF Cardiff Oncology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213037 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.6%
TTM net income YoY25.3%
TTM EPS YoY31.6%
Revenue 3-yr CAGR6.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-7,068.2%
Net margin-6,735.2%
FCF margin—
EBITDA margin-7,005.5%
Returns
ROE-97.9%
ROA-75.2%
ROIC (approx.)-114.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets22.8%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.06x
Accruals ratio4.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $171,000 | $104,000 | $41,000 | $243,000 | $120,000 | $121,000 | $109,000 | $151,000 |
| R&D expense | $5.03M | $5.92M | $6.76M | $5.08M | $8.20M | $11.58M | $10.48M | $9.71M |
| SG&A expense | $4.36M | $3.80M | $6.13M | $3.00M | $3.90M | $3.32M | $4.01M | $3.01M |
| Operating income | -$9.22M | -$9.62M | -$12.85M | -$7.83M | -$11.97M | -$14.78M | -$14.38M | -$12.57M |
| Net income | -$8.86M | -$9.23M | -$12.35M | -$7.22M | -$11.26M | -$13.94M | -$13.43M | -$11.79M |
| EBITDA | -$9.13M | -$9.53M | -$12.76M | -$7.74M | -$11.88M | -$14.68M | -$14.29M | -$12.48M |
| EPS (basic) | -0.12 | -0.14 | -0.18 | — | -0.17 | -0.21 | -0.20 | — |
| EPS (diluted) | -0.12 | -0.14 | -0.18 | — | -0.17 | -0.21 | -0.20 | — |
| Weighted avg. shares (diluted) | 76.18M | 68.40M | 68.35M | — | 66.88M | 66.53M | 66.52M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $12.06M | $9.20M | $8.54M | $17.47M | $10.13M | $10.78M | $24.09M | $51.47M |
| Short-term investments | $21.73M | $25.32M | $37.51M | $40.83M | $50.46M | $60.17M | $55.79M | $40.28M |
| Receivables | $90,000 | $189,000 | $191,000 | $182,000 | $254,000 | $526,000 | $405,000 | $773,000 |
| Current assets | $35.03M | $35.59M | $47.34M | $60.13M | $61.80M | $73.70M | $82.71M | $95.05M |
| PP&E, net | $364,000 | $450,000 | $491,000 | $578,000 | $666,000 | $666,000 | $805,000 | $898,000 |
| Total assets | $36.41M | $37.33M | $49.17M | $61.88M | $63.78M | $75.74M | $84.81M | $97.19M |
| Current liabilities | $8.32M | $10.80M | $14.46M | $16.39M | $14.71M | $16.67M | $13.29M | $13.43M |
| Total liabilities | $8.32M | $10.80M | $14.46M | $16.50M | $14.99M | $17.13M | $13.93M | $14.24M |
| Shareholders' equity | $28.10M | $26.53M | $34.71M | $45.39M | $48.79M | $58.61M | $70.88M | $82.95M |
| Shares outstanding | 77.80M | 68.50M | 68.37M | 68.31M | 67.09M | 66.53M | 66.53M | 66.52M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.87M | -$11.77M | -$12.29M | -$5.97M | -$10.83M | -$8.33M | -$12.79M | -$10.27M |
| Capital expenditure | $4,000 | — | — | $0 | $18,000 | — | — | $0 |
| Free cash flow | -$9.88M | — | — | -$5.97M | -$10.85M | — | — | -$10.27M |
| Investing cash flow | $3.61M | $12.27M | $3.26M | $10.75M | $10.16M | -$4.98M | -$14.58M | $4.51M |
| Financing cash flow | $9.13M | $149,000 | $105,000 | $2.55M | $25,000 | $0 | $3,000 | $44.19M |
| Depreciation & amortization | $88,000 | $87,000 | $87,000 | $88,000 | $89,000 | $94,000 | $93,000 | $96,000 |
| Stock-based compensation | $1.34M | $920,000 | $1.66M | $1.26M | $1.38M | $1.68M | $1.36M | $1.20M |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.